The Scientific Advisory Board (SAB) assists the Management Board and the JPIAMR initiative in all matters of scientific interest, including establishing the Strategic Research Agenda (SRA), and proposing scientific priorities based on societal needs and new scientific evidence. It supports also the activities to implement the SRA. The Scientific Advisory Board (SAB) is chaired by Jean-Yves Madec.
Jordi Vila is the Head of the Department of Clinical Microbiology of the Hospital Clinic in Barcelona, Full Professor of the School of Medicine, University of Barcelona, and Research Professor in the Institute for Global Health (ISGlobal) of Barcelona, Spain. His main field of interest is the development of new drugs against MDR bacteria and molecular tools for rapid diagnosis of infectious disease. Jordi Vila was the Programme Director of the Congress of ESCMID from 2009 to 2014. He has published 415 articles in peer-reviewed journals. He has patented two molecules.
A native of Montréal, Ed Topp obtained his PhD from the Department of Microbiology at the University of Minnesota in 1988. Ed is a principal research scientist with Agriculture and Agri-Food Canada (AAFC) and has courtesy professorship appointments in the Department of Biology at the University of Western Ontario in London Canada, and the Department of Soil and Water Sciences at the University of Florida in Gainesville. Ed’s research concerns the interface between agriculture and human and environmental health, and has generated over 260 co-authored publications. In the last decade he has notably led several national studies concerning the fate and management in agro-ecosystems of pharmaceuticals and pathogenic and antibiotic-resistant bacteria carried in organic fertilizers of animal and human [biosolids] origin. Ed has organized a number of international workshops and conference sessions concerning antibiotic resistance, agriculture, and the environment. He is the project coordinator for the Genomics Research and Development Initiative project on antimicrobial resistance, a key component of the innovation pillar of the Canadian Federal Framework for action on antimicrobial resistance. Ed is a member of the Science Advisory Board for JPIAMR, and a designated FAO/WHO “expert” for foodborne antimicrobial resistance. He is a Past-President  of the Canadian Society of Microbiologists, recently received the AAFC ‘Gold Harvest Award’ for career achievement, the Canadian Public Service Award for Excellence for research contributions, and was elected to the Academie d’Agriculture de France.
Evelina Tacconelli (MD, PhD) is Professor of Infectious Diseases, Head of the Division of Infectious Disease and Medical Director of the Comprehensive Infectious Diseases Center (CIDiC) at the University Hospital of Tübingen, Germany. She has been Lecturer on Medicine at the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA. She was recipient of award from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) for research excellence. Consultant for WHO and ECDC on antimicrobial resistance and infection control. Main areas of her scientific interest are epidemiology, clinical and therapeutic aspects of healthcare-associated infections and preventive measures aimed to reduce the spreading of antibiotic-resistant bacteria. She is the ESCMID Education Officer for Infectious Diseases and Clinical Microbiology. Author and co-author of more than 150 papers listed in SCI-JCR and NIH Medline.
Constance Schultsz is a medical microbiologist at the Amsterdam UMC, University of Amsterdam, which she joined in 2008. Since 2016, she has been a Professor of Global Health and Deputy Head of the Department of Global Health, and Executive Board Member of the Amsterdam Institute for Global Health and Development (AIGHD). From 2003 to 2008, she headed the Microbiology Department at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Her research interests include antimicrobial drug resistance and emerging infectious diseases, which she studies in an international context using interdisciplinary approaches, ranging from molecular biology studies to implementation research. She carries out her research in collaboration with epidemiologists, clinicians, biologists, social scientists such as anthropologists and economists, and computational scientists.
With a background in health psychology and behavioural science, Annegret Schneider applies empirical evidence and theory to improve infection prevention and control. Anngret Schneider is currently working in communication science at the Robert Koch Institute. From 2016 to 2018, she was a Research Associate at University College London carrying out research on infection prevention and control interventions and providing behavioural science expertise to a multi-disciplinary Health Protection Research Unit. At UCL, she supervised a qualitative study of antibiotic stewardship that was awarded the Antibiotic Guardian Award 2018. She has also been a consultant for UK policy agencies on the role of behavioural science to tackle antibiotic resistance. Prior to this, she was a Research Fellow at the University of Surrey, where she tested an eHealth intervention for patients with cancer in an EU-funded randomised control trial and completed her PhD at the Peninsula College of Medicine and Dentistry on patient experiences and anxieties in the dental setting.
Luísa Vieira Peixe
Luísa Vieira Peixe, PharmD, PhD, is Professor of Bacteriology at University of Porto, Portugal. She leads a research team that have been actively contributing to the understanding of the ecology, evolution and dynamics of antimicrobial resistance through different niches. Member of several Portuguese and international scientific committees (e.g. Biohazard Panel of the European Food Safety Authority) and associations and regularly acting as a referee of different journals and evaluator of national and international research funded programs in the field of microbiology and antimicrobial resistance.
Professor Katherine Payne was awarded a personal chair in health economics at The University of Manchester in August 2010. Katherine is also a registered pharmacist and was awarded the status of Fellow of the Royal Pharmaceutical Society in 2016. She is now based within the Manchester Centre for Health Economics at The University of Manchester. She holds honorary positions with: the School of Pharmacy, University of Nottingham; PHG Foundation, Cambridge; Central Manchester University Hospitals NHS Foundation Trust; and Nowgen, Manchester. Katherine has an interest in the economics of genomic technologies and services and the application to precision medicine. Katherine has an interest in the use of economic evidence to inform decision-making in practice and was a member of a NICE Technology Appraisal Committee between October 2003 and 2012. Katherine has been a member of national funding review panels for projects on the economics of personalised medicine for Canada, UK, The Netherlands, France and Luxembourg. Katherine also has an established interest in communicating the methods and application of economic evaluation to healthcare professionals, including pharmacists, and members of the public.
Marc Lemonnier is the CEO and co-founder of Antabio, a leading European company in antibiotic development, and a member of the Board of the European Alliance of Biopharmaceutical companies combating Anti-Microbial resistance (BEAM Alliance). A molecular microbiologist by training, Marc is the author of numerous peer-reviewed articles in the field of pathogenic bacterial infections and their biology. Prior to founding Antabio, Marc held different research positions at various institutions globally such as CNRS and Inserm (France), CSIC (Spain) and Emory University (USA). Under Marc’s leadership, Antabio has attracted double-digit million funding and received numerous awards including a CARB-X award (2017), the BIOVISION Investment Conference Award (2016), the “Concours Mondial de l’Innovation” Worldwide Innovation Challenge (2014), and two Seeding Drug Discovery Awards from the Wellcome Trust (2013 and 2015).
Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C., and a senior research scholar at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Strathclyde in Scotland and at the University of Kwazulu Natal in South Africa. Laxminarayan is founder of HealthCubed, which works to improve access to healthcare and diagnostics worldwide. Since 1995, Ramanan Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource. His work encompasses extensive peer-reviewed research, public outreach, and direct engagement in eleven countries in Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a widely viewed TED talk) and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policymakers worldwide and to the United Nations General Assembly in September 2016. He has served on the U.S. President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group and is currently a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance. He is a series editor of the Disease Control Priorities for Developing Countries, 3rd edition.
Christa Greko is an Associate Professor at the Department of animal health and antimicrobial strategies, Strama VL, National Veterinary Institute (SVA) Uppsala, Sweden. In this position, she supports a network working to contain antimicrobial resistance in veterinary medicine and food (the network Strama VL). Other tasks at SVA, now and previously are risk profiles, expert opinions and other forms of expert advice, monitoring of sales of antibiotics and of antibiotic resistance, policy work and risk communication nationally and internationally. She has previously been involved with ReAct through Uppsala University, and held positions at the Swedish university of agricultural sciences (SLU) as well as Universidad central de venezuela. Christina has conducted research within the areas of diagnostic clinical bacteriology, pharmacokinetics/pharmacodynamic relationships of antimicrobials, antimicrobial resistance including its epidemiology, and usage of antimicrobials.
Ana Maria De Roda Husman
Prof.dr. Ana Maria de Roda Husman has been the Head of the dept. Environment at the Laboratory for Zoonoses and Environmental Microbiology (NL CIDC) since 2009 overseeing research and policy advise on public health risks associated with exposure to pathogens in soil, water and air. She holds Chair in Global changes and Environmental infectious diseases at UU IRAS. As Director of the WHO Collaborating Centre for Risk Assessment of Pathogens in Water and Food ao with WHO and UNC she has organised and chaired the workshop on ‘Developing a Research Agenda for Water, Sanitation and Hygiene (WASH) and Antimicrobial resistance (AMR)’ at the 18th IWA International symposium on Health related Water Microbiology in September 2015 which has led to a peer reviewed article as one of the WHO GAP actions on Combating AMR and WaSH. She presented the Key note regarding The global perspective on AMR and the role of the environment at the Uppsala Health Summit June 2015 A world without antibiotics. She has contributed to the book on AMR control 2016 with a publication on Risk assessment and risk management of AMR in the environment presented at the World Health Assembly of May 2016 and at the Beijing G20. Risk assessment has been one of her focus areas for almost 20 years which has led to numerous publications and key notes.
Rafael Cantón, PhD, is the Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal (Madrid, Spain) and is associated Professor of Clinical Microbiology at School of Pharmacy at Complutense University (Madrid, Spain). His research activity is developed within the Spanish Network for Research in Infectious Diseases (REIPI, http://reipi.org/) and Institute Ramón y Cajal for Health Research (IRYCIS, http://www.irycis.org) and is focussed on antimicrobial susceptibility testing and surveillance, characterization of antimicrobial resistance mechanisms and interplay with high-risk clones, and respiratory tract infections (mainly in cystic fibrosis and bronchiectasis patients). He has participated in different EU projects from 6th (COBRA-LSHM-CT-2003-503335) and 7th FP (TROCAR-223031, R-GNOSIS-FP7-HEALTH-F3-2011-282512, MON4STRAT-FP7-HEALTH-2013-INNOVATION-1-602906-2) programs and is currently part of H2020 (FAST-BACT-730713, BADGER-784514) and IMI (COMBATE-CARE-115620-2, iABC-115721-2) projects. He has published more than 440 articles in medical journals and 50 chapters in teaching books.
He is currently Clinical Data Coordinator of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) and member of the Spanish Antimicrobial Committee (COESANT). He has been Chairman of EUCAST (2012-2016), President of Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC, 2016-2017), Founder President of the Study Group of Mechanisms of Action and Resistance of Antimicrobials (GEMARA) from SEIMC (2000-2005), associated editor of Clinical Microbiology and Infection journal and member of the editorial board of Journal Clinical Microbiology. He is coeditor of the Clinical Microbiology Procedures of the SEIMC (www.seimc.org).
Dr. Brown’s research interest is the complex biology that underlies bacterial survival strategies. He and his research team aim to understand and subvert these systems in drug resistant superbugs. To this end the Brown lab research group is using tools of chemical biology and molecular genetics to probe poorly understood aspects of bacterial physiology. The overriding goal of these studies is to contribute fresh directions for new antibiotics. Dr. Brown has been the recipient of a number of awards and is a very active participant in the university and research communites. He is a Fellow of the American Academy of Microbiology and has received the Canadian Society of Microbiologists Murray Award for career achievement, the Canadian Society for Molecular Biosciences Merck Frosst Prize for new investigators and a Canada Research Chair in Microbial Chemical Biology. Dr. Brown is a former department Chair and has served on advisory boards for a variety of companies as well as national and international associations, including: a term as President of the Canadian Society of Molecular Biosciences; member of the Medical Review Panel of the Gairdner Foundation; and member of the Institute of Infection and Immunity Advisory Board of the Canadian Institutes of Health Research. Currently, he is serving as one of 15 Chairs nationwide on the latter organization’s College of Reviewers and on the Editorial Advisory Board of the journal ACS Infectious Diseases.
Till Bachmann is Deputy Head of the Division of Infection and Pathway Medicine, Programme Director of Clinical Microbiology and Infectious Diseases and Biomedical Sciences MSc and PhD programmes at The University of Edinburgh and the Zhejiang University – University of Edinburgh Institute in China. Till has a PhD on biosensors from research at University of Stuttgart and The University of Tokyo and a German Habilitation in Analytical Biotechnology. He is an expert in point of care detection of infectious diseases and antimicrobial resistance, conducting research at the interface of biomarkers and rapid diagnostics. Till is coordinator of the UK-India project ‘DOSA - Diagnostics for One Health and User Driven Solutions for AMR’, the JPIAMR Network AMR Dx Global, succeeding the JPIAMR Transnational Working Group on Rapid Diagnostic Tests. Till fulfils a variety of industrial and institutional advisory roles worldwide. As such he is member of the UK AMR Diagnostic Collaborative, Panel Member for the Longitude Prize on Antibiotics, Scientific Advisory Board member Devices & Diagnostics under National Biopharma Mission of the Indian BIRAC, and founder of AMR DxC - the Antimicrobial Resistance Diagnostics Challenge competition.
DVM, PhD, molecular microbiologist, Research Director at the French Agency for Food, Environmental and Health Safety (Anses), Lyon, France. National coordinator of all scientific activities dealing with surveillance, reference and research on AMR at Anses. In particular, coordinator of the National Monitoring Network for AMR in animal pathogens (Resapath). Head of the AMR and Virulence Unit, with research interests on molecular genetics and epidemiology of AMR in bacteria of animal origin (commensal, pathogenic, zoonotic) and issues regarding the animal-human transfer of AMR. Member of several expert groups and committees on AMR and antibiotic use in animals and humans in France and Europe and active participant/leader in several European scientific projects.